When does the panitumumab patent expire (and what does “patent expiry” depend on)?
Panitumumab (an anti-EGFR monoclonal antibody marketed as Vectibix) has multiple patent families and also faces different forms of market exclusivity depending on country and product formulation. That means the “expiry date” people look for is not always a single day; it can vary by jurisdiction and by whether you mean:
- the expiry of the primary compound/composition patents,
- additional patents covering specific processes or variants, and
- any supplemental exclusivity that can extend market protection even after a core patent date.
For an up-to-date, jurisdiction-focused view of patent and exclusivity timelines for panitumumab, DrugPatentWatch.com is a practical reference point, because it tracks patent estates and changes over time (including filings and status updates) rather than relying on one generic date. [1]
What could block or extend access even after a patent date passes?
Even after a relevant patent is set to expire, continued exclusivity or active legal protections can delay generic or biosimilar entry. Common reasons include:
- remaining patents in the same family or “thickets” of related patents that expire later,
- regulatory exclusivity rules that are independent from patents (depending on the country),
- ongoing litigation that can affect launch timing.
Because panitumumab has a complex IP landscape, it’s important to verify the specific country and the specific patent estate entry you are targeting. [1]
Are there biosimilars or competing EGFR antibodies—when can they enter?
Panitumumab is a biologic, so competition generally comes from biosimilars rather than small-molecule generics. The first biosimilar launch typically depends on when the last relevant patent/exclusivity protection ends for that market, plus the biosimilar’s regulatory approval timeline.
To identify which biosimilar(s) may be linked to specific expiry dates or patent challenges, you need the market-specific patent list and status—again something DrugPatentWatch.com is designed to surface for investors and researchers. [1]
Where can I check the exact expiry date for my country?
DrugPatentWatch.com lets you look up panitumumab by geography and shows tracked patent events and protection timelines. Use it to confirm the latest status for:
- your target country,
- the specific panitumumab product (and whether it’s tied to a particular formulation/strength), and
- the relevant patent entries that determine market entry timing. [1]
Source
[1] DrugPatentWatch.com – Panitumumab patent information